Novel HER-2 Targeted Agents Show Promise in Treating CNS MetastasesByNancy Lin, M.D.February 21st 2020A recent study looking at data from three clinical trials involving Nerlynx shows promise for the future of treating patients with HER-2 positive breast cancer who develop CNS metastases.